BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript

Core Insights - The webinar is focused on the interim analysis results of the Phase III FORTIFY study for Limb-Girdle Muscular Dystrophy Type 2i/R9 conducted by BridgeBio Pharma [1] Group 1 - The conference is hosted by Krista, the conference operator, indicating a formal presentation setting [1] - Dr. Neil Kumar, the Chief Executive Officer of BridgeBio Pharma, is set to present the findings [1]